Evidence map›Paper›PMID 38988008›Full record

ArticleBrain pathology (Zurich, Switzerland)2025

Upper motor neuron-predominant motor neuron disease presenting as atypical parkinsonism: A clinicopathological study.

Aya Murakami, Shunsuke Koga, Shinsuke Fujioka, Adrianna E White, Kevin F Bieniek, Hiroaki Sekiya, Mariely DeJesus-Hernandez, NiCole A Finch, Marka van Blitterswijk, Masataka Nakamura and 4 more

Abstract read
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Aya MurakamiDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Shunsuke KogaDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.ORCID 0000-0001-8868-9700
Shinsuke FujiokaDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Adrianna E WhiteDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Kevin F BieniekDepartment of Pathology & Laboratory Medicine, University of Texas Health Science Center San Antonio, Texas, USA.
Hiroaki SekiyaDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Mariely DeJesus-HernandezDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
NiCole A FinchDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Marka van BlitterswijkDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Masataka NakamuraDepartment of Neurology, Kansai Medical University, Osaka, Japan.
Yoshio TsuboiDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
Melissa E MurrayDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Zbigniew K WszolekDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.ORCID 0000-0001-7189-7917

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI Bradley F Boeve · 2019 to 2026
$120.9M
Vascular Structure and Function in Cognitive AgingP01AG003949 · NIA · YESHIVA UNIVERSITY · PI Charles B Hall · 1985 to 2026
$73.9M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2019 to 2026
$33.5M
Project 2: Identifying genes and Pathways that impact Tau Toxicity in FTDU54NS100693 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2016 to 2020
$6.2M
The Contribution of Age-Related Taupahtoies to Alzheimer's Disease-SupplementR01AG062348 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CRARY, JOHN FONDA, DICKSON, DENNIS WILLIAM · 2018 to 2022
$4.5M
The Contribution of Age-Related Tauopathies to Alzheimer's DiseaseRF1AG062348 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI John Fonda Crary, DENNIS WILLIAM DICKSON · 2023 to 2026
$4.0M
Frontotemporal dementia and related disorders: transcriptomic profiling, biomarker discovery, and mechanistic insightR01NS121125 · NINDS · MAYO CLINIC JACKSONVILLE · PI GENDRON, TANIA FRANCE, VAN BLITTERSWIJK, MARKA · 2021 to 2025
$3.9M
C9orf72-mediated features, transcriptomic signatures, and translational studies for frontotemporal dementia and related disordersRF1NS123052 · NINDS · MAYO CLINIC JACKSONVILLE · PI VAN BLITTERSWIJK, MARKA · 2022 to 2022
$2.4M
C9orf72-mediated features transcriptomic signatures and translational studies for frontotemporal dementia and related disordersR01NS123052 · NINDS · MAYO CLINIC JACKSONVILLE · PI Marka Van Blitterswijk · 2025 to 2026
$1.3M
NIA NIH HHS P01 AG003949NIA NIH HHS P30 AG062677NIA NIH HHS R01 AG062348NIA NIH HHS RF1 AG062348NIA NIH HHS U19 AG063911NIH HHS 1U19AG063911NIH HHS FAIN: U19AG063911NIH HHS P01-AG03949NIH HHS P30-AG062677NIH HHS R01-AG062348NIH HHS R01-NS121125NIH HHS RF1-NS123052NIH HHS U54-NS100693NINDS NIH HHS R01 NS121125NINDS NIH HHS R01 NS123052NINDS NIH HHS RF1 NS123052NINDS NIH HHS U54 NS100693
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by upper and lower motor neuron signs. There are, however, cases where upper motor neurons (UMNs) are predominantly affected, leading to clinical presentations of UMN-dominant ALS or primary lateral sclerosis. Furthermore, cases exhibiting an UMN-predominant pattern of motor neuron disease (MND) presenting with corticobasal syndrome (CBS) have been sparsely reported. This study aims to clarify the clinicopathological features of patients with UMN-predominant MND. We reviewed 24 patients with UMN-predominant MND with TDP-43 pathology in the presence or absence of frontotemporal lobar degeneration. Additionally, we reviewed the medical records of patients with pathologically-confirmed corticobasal degeneration (CBD) who received a final clinical diagnosis of CBS (n = 10) and patients with pathologically-confirmed progressive supranuclear palsy (PSP) who received a final clinical diagnosis of PSP syndrome (n = 10). Of 24 UMN-predominant MND patients, 20 had a clinical diagnosis of an atypical parkinsonian disorder, including CBS (n = 11) and PSP syndrome (n = 8). Only two patients had antemortem diagnoses of motor neuron disease. UMN-predominant MND patients with CBS less frequently exhibited apraxia than those with CBD, and they were less likely to meet clinical criteria for possible or probable CBS. Similarly, UMN-predominant MND patients with PSP syndrome less often met clinical criteria for probable PSP than PSP patients with PSP syndrome. Our findings suggest that UMN-predominant MND can mimic atypical parkinsonism, and should be considered in the differential diagnosis of CBS and PSP syndrome, in particular when criteria are not met.

Indexed as

Motor Neuron DiseaseParkinsonian DisordersAgedAged, 80 and overAmyotrophic Lateral SclerosisCorticobasal DegenerationDiagnosis, DifferentialDNA-Binding ProteinsFemaleHumansMaleMiddle AgedMotor NeuronsSupranuclear Palsy, ProgressiveDNA-Binding ProteinsTARDBP protein, humanatypical parkinsonismTDP‐43upper‐motor‐neuron‐predominant motor neuron disease

Identifiers

PMID38988008
PMCPMC11669411

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.